CRIP2

CRIP2 is a nuclear LIM-domain protein that functions principally as a transcriptional repressor restraining angiogenic and metabolic programs in cancer (PMID:21540330, PMID:29662084). It physically interacts with NF-κB/p65 and blocks its DNA binding at the promoters of proangiogenic cytokines IL6, IL8, and VEGF, thereby suppressing tumorigenesis and angiogenesis (PMID:21540330). In a parallel repressive role, CRIP2 cooperates with HOXA9 at glycolytic gene promoters (HK2, GLUT1, PDK1) to impede HIF-1α binding and dampen glycolytic gene expression, situating it within a miR-365–HOXA9–HIF-1α axis (PMID:29662084). CRIP2 is also a nuclear copper-binding protein that receives copper from the chaperone Atox1; copper loading drives a conformational change and ubiquitin-mediated proteasomal degradation of CRIP2, and its loss elevates ROS and activates autophagy, identifying CRIP2 as an autophagy suppressor (PMID:34550632). In developmental settings, CRIP2 represses Notch signaling through NF-κB to permit hematopoietic stem/progenitor cell emergence from hemogenic endothelium (PMID:41601327) and represses ECM gene expression (versican a, has2) during atrioventricular valve formation (PMID:24823359). In endothelial cells it additionally interacts with cytoskeletal proteins KRT8 and VIM and supports migration and proliferation through VEGFA/CDC42 and SRF-linked signaling (PMID:40074973).

1. 2011 High

   Established CRIP2's core molecular function: how a LIM-domain protein could suppress tumors was unknown, and this work showed it acts as a transcriptional repressor of NF-κB/p65 at proangiogenic cytokine promoters.

   Evidence Microcell-mediated chromosome transfer, reciprocal Co-IP, ChIP at IL6/IL8/VEGF promoters, and in vivo tumor suppression assays in cancer cell lines

   PMID:21540330

   Open questions at the time

   • Structural basis of the CRIP2–p65 interaction not defined
   • Whether repression generalizes beyond the named cytokine promoters not established
2. 2011 Medium

   Tested where CRIP2 acts and its cellular consequence; demonstrated nuclear localization in esophageal carcinoma and that overexpression triggers caspase-3/9-dependent apoptosis.

   Evidence Subcellular fractionation and Western blot for active caspases with CRIP2 overexpression in ESCC cells

   PMID:22154084

   Open questions at the time

   • Direct transcriptional targets driving apoptosis not identified
   • Link between nuclear repressor activity and caspase activation not mechanistically connected
3. 2011 Low

   Probed a non-nuclear role; in mouse cardiomyocytes Crip2 colocalizes with cardiac troponin T at sarcomeric thin filaments, hinting at a structural function distinct from transcriptional repression.

   Evidence Immunofluorescence co-localization in mouse heart sections

   PMID:21601656

   Open questions at the time

   • Co-localization only, no functional perturbation
   • No biochemical evidence of direct sarcomeric binding
4. 2014 Medium

   Asked what CRIP2 does in cardiac development; loss-of-function in zebrafish showed it represses ECM genes (versican a, has2) in AV canal endocardium required for valve formation, without affecting bmp4/tbx2b/notch1b.

   Evidence Morpholino knockdown, in situ hybridization, and heart-looping phenotype analysis in zebrafish

   PMID:24823359

   Open questions at the time

   • Direct binding of CRIP2 at ECM gene promoters not shown
   • Transcriptional partners in endocardium not identified
5. 2016 Medium

   Placed CRIP2 within an upstream regulatory circuit; showed miR-449a directly suppresses CRIP2 and that restoring CRIP2 reduces breast cancer growth and angiogenesis via NF-κB/p65-mediated VEGF transcription.

   Evidence Luciferase 3'UTR reporter, stable CRIP2 transfection, and mouse xenograft growth/angiogenesis assays

   PMID:26934316

   Open questions at the time

   • NF-κB/VEGF mechanism inferred without ChIP in this study
   • Other miR-449a targets contributing to phenotype not excluded
6. 2018 High

   Extended CRIP2 repressor function to metabolism; demonstrated it cooperates with HOXA9 at glycolytic promoters to exclude HIF-1α, defining a miR-365–HOXA9–HIF-1α axis controlling glycolytic reprogramming.

   Evidence Reciprocal Co-IP, ChIP at HK2/GLUT1/PDK1 promoters, luciferase reporters, and in vivo glycolysis assays

   PMID:29662084

   Open questions at the time

   • Whether CRIP2 directly contacts HIF-1α or only competes via HOXA9 not resolved
   • Stoichiometry of the CRIP2–HOXA9 complex unknown
7. 2021 High

   Revealed a metal-sensing dimension; APEX2 proximity labeling and biochemistry showed CRIP2 binds copper received from Atox1, undergoes conformational change and proteasomal degradation, and acts to suppress ROS and autophagy.

   Evidence APEX2 proximity labeling with MS, Co-IP, circular dichroism, proteasome inhibition, ROS measurement, and autophagy flux assays

   PMID:34550632

   Open questions at the time

   • Copper-binding residues and the responsible E3 ligase not identified
   • Mechanistic link between CRIP2 degradation and autophagy induction undefined
8. 2025 Medium

   Characterized CRIP2 in endothelial cell biology; Co-IP and zebrafish loss-of-function tied it to cytoskeletal proteins KRT8/VIM and to VEGFA/CDC42 and SRF-linked migration and proliferation signaling.

   Evidence Co-IP in HUVECs, zebrafish crip2 loss-of-function, Western blot for pathway components, and adhesion/migration/proliferation assays

   PMID:40074973

   Open questions at the time

   • Direct versus indirect nature of multiple signaling effects not separated
   • Whether cytoskeletal interactions are nuclear or cytoplasmic not resolved
9. 2025 Low

   Positioned CRIP2 downstream of MAP2K4 in breast cancer; overexpression studies showed CRIP2 inhibits p65 phosphorylation and reverses MAP2K4-driven malignant phenotypes.

   Evidence Western blot for p-p65 and CCK-8/EdU/Transwell assays with MAP2K4 and CRIP2 overexpression in TNBC cells

   PMID:41210648

   Open questions at the time

   • MAP2K4–CRIP2 link based on expression changes without direct binding evidence
   • Mechanism of CRIP2-mediated p65 dephosphorylation not defined
10. 2025 Low

    Implicated CRIP2 in therapy response; knockdown sensitized prostate cancer cells to the PARP inhibitor olaparib, identifying it as a mediator of drug resistance.

    Evidence In vitro cell viability drug-sensitivity assays after CRIP2 knockdown in LNCaP and C4-2B cells

    PMID:41132344

    Open questions at the time

    • No mechanistic pathway linking CRIP2 to olaparib resistance delineated
    • Not validated in vivo
11. 2026 High

    Defined a developmental hematopoietic role; CRISPR loss-of-function and epistasis showed Crip2 (with Crip3) is required for HSPC emergence by repressing Notch through NF-κB, with Notch inhibition rescuing the defect.

    Evidence Zebrafish CRISPR alleles, single-cell RNA-seq of endothelial cells, and pharmacological Notch-inhibitor rescue/epistasis

    PMID:41601327

    Open questions at the time

    • Direct molecular target of CRIP2 within the NF-κB–Notch axis not identified
    • Functional redundancy with Crip3 not fully dissected

• How CRIP2's nuclear transcriptional repressor activity, copper-sensing/degradation, and cytoplasmic cytoskeletal roles are integrated into a single regulatory logic remains unresolved.
• No structure of CRIP2 bound to p65 or HOXA9
• E3 ligase and copper-binding residues unidentified
• Whether copper-dependent degradation modulates its transcriptional repressor output untested